Alexis Bio
Alexis Bio is a privately held, clinical-stage biotechnology company founded in 2016 and based in Boston. The company claims a robust pipeline but publicly discloses no therapeutic area, products, or pipeline assets. It is pre-revenue and pre-launch with limited public information.
- Company typePrivate
- Founded2016
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Alexis Bio firmographics
Firmographics- Name
- Alexis Bio
- Website
- https://alexisbio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alexis Bio is a privately held, clinical-stage biotechnology company founded in 2016 and based in Boston. The company claims a robust pipeline but publicly discloses no therapeutic area, products, or pipeline assets. It is pre-revenue and pre-launch with limited public information.
- Ownership category
- akta.pro rank
Alexis Bio industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where Alexis Bio is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
Alexis Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Alexis Bio product offering
Product offeringCore offering
Alexis Bio operates as a clinical-stage biotechnology company developing a pipeline of therapeutic candidates. The company is in a pre-launch state, with its public website currently showing only a Coming Soon page and no specific product candidates, indications, or modalities disclosed. Its business centers on advancing internal drug development programs toward future clinical and commercial milestones.
Product overview
Alexis Bio is a pre-launch company currently displaying a Coming Soon landing page. Based on the limited source data available, no specific products, services, or named offerings have been publicly disclosed. The company appears to be in the early stages of development with no product portfolio details accessible from the current landing page.
Differentiator
Problem solved
Functional benefit
Companies that use Alexis Bio
Customer profileIdeal customer profiles2 records
Alexis Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Alexis Bio partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Alexis Bio competitors and assessment
Company assessmentEmerging players
- MorphImmune: Emerging clinical-stage biotech developing targeted immunotherapies using a morpholino-based delivery platform. Comparable as a small, capital-efficient clinical-stage company with a novel therapeutic platform and a pipeline in early clinical development.
Direct peers
- Candel Therapeutics: Clinical-stage immuno-oncology company based in the Greater Boston area developing viral immunotherapies. Directly comparable as a small clinical-stage biotech with a Boston footprint, a pipeline of investigational therapies, and a similar capital-efficient operating posture.
- Foghorn Therapeutics: Clinical-stage Cambridge, MA-based biotech developing medicines targeting the chromatin regulatory system in oncology. Comparable in stage, geography, headcount range, and approach as a lean, pipeline-focused clinical-stage company.
- C4 Therapeutics: Clinical-stage Boston-area biotech developing targeted protein degraders for cancer and other diseases. Comparable as a small, clinical-stage Boston biotech with a focused pipeline advancing through early-phase trials on a capital-efficient basis.
- Compass Therapeutics: Clinical-stage Boston-based biotech developing antibody-based therapeutics for cancer. Comparable in stage (clinical), geography (Boston), size, and pipeline orientation as a lean, R&D-focused clinical-stage company.
- Omega Therapeutics: Clinical-stage Cambridge, MA-based biotech developing programmable epigenetic medicines. Comparable as a small clinical-stage Boston-area biotech with a focused pipeline of novel mechanism therapeutics advancing through early clinical development.
- Vor BioPharma: Clinical-stage Boston-area biotech developing engineered hematopoietic stem cell therapies for hematologic cancers and autoimmune diseases. Directly comparable as a small, capital-efficient clinical-stage biotech operating out of the Greater Boston cluster with a pipeline in early-to-mid stage trials.
- Cogent Biosciences: Clinical-stage Boston-area precision oncology company advancing targeted therapies through Phase 1/2 trials. Comparable in stage (clinical), geography (Boston/Cambridge), and lean operating model with a small employee base focused on pipeline advancement.
Broad incumbents
- Tarsus Pharmaceuticals: Clinical-stage biopharmaceutical company that advanced multiple programs through late-stage development and is broader/more mature than Alexis Bio. Useful as a reference for capital and execution patterns of a Boston-area clinical-stage biotech that has successfully reached commercial readiness.
- Kymera Therapeutics: Clinical-stage Boston-area biotech developing targeted protein degraders with a more advanced pipeline and broader investor base. Comparable in modality, geography, and stage, but more advanced and well-capitalized — useful as an upper-bound reference for Alexis Bio's potential trajectory.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Alexis Bio social profiles
Digital presenceAlexis Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alexis Bio leadership team
Management profileNumber of profiles
Profiles2 records
Alexis Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alexis Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alexis Bio
What does Alexis Bio do?
Alexis Bio operates as a clinical-stage biotechnology company developing a pipeline of therapeutic candidates. The company is in a pre-launch state, with its public website currently showing only a Coming Soon page and no specific product candidates, indications, or modalities disclosed. Its business centers on advancing internal drug development programs toward future clinical and commercial milestones.
When was Alexis Bio founded?
Alexis Bio was founded in 2016. It employs 11 to 50 people.
Where is Alexis Bio based?
Alexis Bio is headquartered in Boston, United States, in the North America region.
Who are Alexis Bio's main competitors?
MorphImmune is listed as an emerging player. Direct peers are Candel Therapeutics, Foghorn Therapeutics, C4 Therapeutics, Compass Therapeutics, Omega Therapeutics, Vor BioPharma and Cogent Biosciences. Broad incumbents are Tarsus Pharmaceuticals and Kymera Therapeutics.
Does Alexis Bio have an API?
No public API is recorded for Alexis Bio.
What industry is Alexis Bio in?
Alexis Bio's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 541714 and its SIC code is 2834.